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Nucleotide-binding oligomerization domain-containing protein (Nod) 2 is an intracellular pattern recognition receptor, which
recognizes muramyl dipeptide (N-Acetylmuramyl-L-Alanyl-D-Isoglutamine: MDP), a bacterial peptidoglycan component, and
makes a NF-𝜅B-activating complex called nodosome with adaptor protein RICK (RIP2/RIPK2). Nod2 mutants are associated with
the autoinflammatory diseases, Blau syndrome (BS)/early-onset sarcoidosis (EOS). For drug discovery of BS/EOS, we tried to
develop Nod2-nodosome in a cell-free system. FLAG-tagged RICK, biotinylated-Nod2, and BS/EOS-associated Nod2 mutants
were synthesized, and proximity signals between FLAG-tagged and biotinylated proteins were detected by amplified luminescent
proximity homogeneous assay (ALPHA). Upon incubation with MDP, the ALPHA signal of interaction between Nod2-WT and
RICK was increased in a dose-dependent manner. The ALPHA signal of interaction between RICK and the BS/EOS-associated
Nod2 mutants was more significantly increased than Nod2-WT. Notably, the ALPHA signal between Nod2-WT and RICK was
increased upon incubation with MDP, but not when incubated with the same concentrations, L-alanine, D-isoglutamic acid, or the
MDP-D-isoform. Thus, we successfully developed Nod2-nodosome in a cell-free system reflecting its function in vivo, and it can
be useful for screening Nod2-nodosome-targeted therapeutic molecules for BS/EOS and granulomatous inflammatory diseases.
1. Introduction
Nucleotide-binding oligomerization domain-containing pro-
tein (Nod) 2 is a nuclear factor- (NF-) 𝜅B-activating intracel-
lular pattern recognition receptor, which was identified as a
susceptibility gene product of Crohn’s disease, an inflamma-
tory bowel disease [1–3].
Nod2 was reported to be oligomerized with adaptor
protein RICK (RIP2/RIPK2) and IKK complexes, which can
activate NF-𝜅B by muramyl dipeptide (N-Acetylmuramyl-
L-Alanyl-D-Isoglutamine: MDP), one of the components
of bacterial cell-wall peptidoglycan, and is utilized as an
immune-stimulatory adjuvant for vaccination and for devel-
oping antibodies [4–8].
Hindawi Publishing Corporation
e Scientiﬁc World Journal
Volume 2016, Article ID 2597376, 7 pages
http://dx.doi.org/10.1155/2016/2597376
2 The Scientific World Journal
Table 1: Oligonucleotide sequences for plasmid construction.













Underline indicates S1 or T1 sequence.
Bold indicates Kozak consensus sequence.
Italic indicates mutation codons for specific amino acids.
It was also discovered that an autoinflammatory dis-
ease, Blau syndrome (BS)/early-onset sarcoidosis (EOS), was
caused by a point mutation of Nod2, encoding a consti-
tutively active form, resulting in NF-𝜅B activation [9–11].
BS/EOS is a systemic granulomatous disease, and patients
with BS/EOS have nonnecrotizing granulomas of the skin,
eyes, and joints [12]. Other granulomatous inflammatory
diseases were similarly reported to be associated with Nod2
[13, 14]. Therefore, Nod2 has been thought to be involved
in granulomatous disorders [15] and may be an attractive
drug target for treatment of these chronic inflammatory
granulomatous diseases.
Thus,we aimed to develop a reconstituted protein-protein
interaction assay system between wild-type Nod2 and the
BS/EOS-associated mutants of Nod2 and RICK in a cell-free
system, further called the reconstituted Nod2-nodosome in a
cell-free system [16].
2. Materials and Methods
2.1. Plasmid Construction, Site-Specific Mutagenesis for the
BS/EOS-Associated Mutant Nod2, and Protein Synthesis.
The cDNA of human Nod2 and RICK were derived from
pcDNA3-Nod2 and pcDNA3-RICK, kindly provided by Dr.
G Nu´n˜ez (accession number: AF178930 and AF027706).
Each open reading frame, without stop codons, was mod-
ified in a two-step polymerase chain reaction (PCR).
Briefly, the initial PCR product for Nod2-WT was amplified
using the primers: forward S1-Nod2 F: 5󸀠-CCACCCACC-
ACCACCAATGGGGGAAGAGGGTGGTTCAG-3󸀠 and
reverse Nod2-T1(F) R: 5󸀠-TCCAGCACTAGCTCCAGA-
AAGCAAGAGTCTGGTGTCCCT-3󸀠.The initial PCRprod-
uct for Nod2-CARD1+CARD2 (CARDs) was amplified using




The initial PCR product for RICK-WT was ampli-
fied using the primers: forward S1-RICK F: 5󸀠-CCACCC-
ACCACCACCAATGAACGGGGAGGCCATCTG-3󸀠 and
reverse RICK-T1(F) R: 5󸀠-TCCAGCACTAGCTCCAGA-
CATGCTTTTATTTTGAAGTAAATTTA -3󸀠. The ini-
tial PCR product for RICK-CARD was amplified using
the primers: forward S1-RICK (CARD) F: 5󸀠-CCACCC-
ACCACCACCAATGAACGGGGAGGCCATCTG-3󸀠 and
reverse RICK-T1(F) R: 5󸀠-TCCAGCACTAGCTCCAGA-
CATGCTTTTATTTTGAAGTAAATTTA-3󸀠.
The second PCR was carried out using the follow-
ing primer set: attB1-S1: 5󸀠-GGGGACAAGTTTGTACAA-
AAAAGCAGGCTTCCACCCACCACCACCAATG-3󸀠 and
attB2-T1: 5󸀠-GGGGACCACTTTGTACAAGAAAGCTGG-
GTCTCCAGCACTAGCTCCAGA-3󸀠 with the initial PCR
products as templates. These primers are shown in Table 1.
PCR-based site-specific mutagenesis for Nod2-R334W
was amplified by two-step PCR using the following primer
sets: forward S1-Nod2 F: 5󸀠-CCACCCACCACCACCAAT-
GGGGGAAGAGGGTGGTTCAG-3󸀠 and reverse Nod2-
R334W R: 5󸀠-GCACTGCAGCTGCCAGCAGCTGAA-
TGGGAA-3󸀠, and forward Nod2-R334W F: 5󸀠-TTCCCA-
TTCAGCTGCTGGCAGCTGCAGTGC-3󸀠 and reverse
Nod2-T1(F) R: 5󸀠-TCCAGCACTAGCTCCAGAAAG-
CAAGAGTCTGGTGTCCCT-3󸀠 for the first-step overlap-
ping DNA fragment set. PCR-based site-specific mutagenesis
for Nod2-N670K was also amplified by two-step PCR using
the following primer sets: forward S1-Nod2 F: 5󸀠-CCACCC-
ACCACCACCAATGGGGGAAGAGGGTGGTTCAG-3󸀠
and reverse Nod2-N670K R: 5󸀠-TGCTGTGATCTGAAG-
TTTGTGCGGCTCGGC-3󸀠, and forward Nod2-N670K F:
5󸀠-GCCGAGCCGCACAAACTTCAGATCACAGCA-3󸀠
and reverse Nod2-T1(F) R: 5󸀠-TCCAGCACTAGCTCC-
AGAAAGCAAGAGTCTGGTGTCCCT-3󸀠 for the first-step
overlappingDNA fragment set. R334W andN670Kmutated-
Nod2 DNA fragments were amplified by a second PCR step
using the following primer set: attB1-S1: 5󸀠-GGGGACAAG-
TTTGTACAAAAAAGCAGGCTTCCACCCACCACC-
ACCAATG-3󸀠 and attB2-T1: 5󸀠-GGGGACCACTTTGTA-
CAAGAAAGCTGGGTCTCCAGCACTAGCTCCAGA-3󸀠,
from the first-step overlapping DNA fragment sets as
template. These oligonucleotide sequences for mutated Nod2
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are listed in Table 1. PCR products were inserted into a
pDONR221 vector using Gateway BP Clonase II Enzyme
mix (Life Technologies, Carlsbad, CA, USA) to generate
entry clones. Nod2 entry clones, pDONR221-Nod2-WT,
pDONR221-Nod2-R334W, pDONR221-Nod2-N670K, and
pDONR221-Nod2-CARDs, were inserted into pEU-E01-
GW-bls-STOP for cell-free protein expression. RICK entry
clones, pDONR221-RICK-WT and pDONR221-RICK-
CARD, were inserted into pEU-E01-FLAG-GW-STOP, using
the Gateway LR Clonase II Enzyme mix. These constructs
were confirmed by sequencing (Figure 1(c)). The constructed
plasmids were used to synthesize their respective proteins
using the WEPRO1240 Expression Kit (Cell-free, Inc.,
Matsuyama, Japan) and were followed by Western blotting.
2.2. Western Blotting Analysis. A total of 1.5 𝜇g of synthetic
protein was subjected to SDS-PAGE followed by Western
blotting analysis. Protein detection on the blotting mem-
branes was performed using anti-FLAG mAb M2 (Sigma-
Aldrich, St. Louis, MO, USA), followed by peroxidase-
conjugated affinity-purified F(ab󸀠)
2




search, West Grove, PA, USA) for FLAG-tagged proteins,
or HRP-conjugated streptavidin (Nacalai, Kyoto, Japan) for
biotinylated proteins.
2.3. Pull-Down Assay. One-microgram biotinylated-Nod2-
WT (Nod2-WT-Btn) and 1 𝜇g FLAG-tagged RICK-WT
(FLAG-RICK-WT) lysed in 300 𝜇L NP-40 buffer [1% Non-
idet P-40, 142.5mmol/L KCl, 5mmol/L MgCl
2
, 10mmol/L
HEPES (pH 7.6), 0.2mmol/L phenylmethylsulfonylfluoride
(PMSF), and 1mmol/L EDTA] were precipitated with 20 𝜇L
streptavidin-conjugated agarose beads (Invitrogen) with or
without 5.33mg/mLMDP (Sigma-Aldrich) and incubated for
3 hours at 4∘C. The precipitations were subjected to SDS-
PAGE and immunoblotting. Detection on the blotting mem-
branes was performed using anti-FLAG mAb M2 (Sigma-
Aldrich) or anti-Nod2 mAb 2D9 (Cayman Chemical, Ann
Arbor, MI, USA).
2.4. Amplified Luminescent Proximity Homogeneous Assay.
Synthesized protein-protein interactions were assessed
by amplified luminescent proximity homogeneous assay
(ALPHA) (PerkinElmer). A total of 100 ng of each protein
was added to ALPHA buffer [100mM Tris-HCl (pH
8.0), 0.01% (v/v) Tween 20], 1mg/mL BSA, 16.67 𝜇g/mL
streptavidin-coated donor beads (PerkinElmer, Waltham,
MA, USA), 16.67 𝜇g/mL protein-A-conjugated acceptor
beads, and 5 𝜇g/mL anti-FLAG mAb M2 and incubated
in a Shallow Well ALPHAPlate-384 (PerkinElmer) at 25∘C
for 24 hours. Fluorescence emission signals of each well
were measured using an EnSpire Multimode Plate Reader
(PerkinElmer).
2.5. Statistics. Results are presented as the mean and stan-
dard deviation. Levels of significance were evaluated using
Student’s 𝑡-test. A 𝑝 value < 0.05 was considered statistically
significant.
3. Results
3.1. Recombinant Nod2, RICK, and Their Mutant Proteins
Were Successfully Synthesized Using a Wheat Germ Cell-Free
System. The schematics of the C-terminal biotinylated
full-length wild-type Nod2 (Nod2-WT-Btn), full-length
R334W-mutated Nod2 (Nod2-R334W-Btn), full-length
N670K-mutated Nod2 (Nod2-N670K-Btn), and tandem
CARD1- and CARD2-domains-only Nod2 (Nod2-CARDs)
are shown in Figure 1(a). The schematics of the N-terminal
FLAG-tagged full-length RICK (FLAG-RICK-FL) and
CARD-domain-only RICK (FLAG-RICK-CARD) are shown
in Figure 1(b). The plasmids vectors pDONR221-Nod2-
WT, pDONR221-Nod2-R334W, pDONR221-Nod2-N670K,
pDONR221-Nod2-CARDs, pDONR221-RICK-WT, and
pDONR221-RICK-CARD were sequenced and confirmed.
The proper BS/EOS-associated mutation sequences of Nod2
were confirmed (Figure 1(c)). Nod2 and its variants, including
Nod2-WT-Btn, Nod2-R334W-Btn, Nod2-N670K-Btn, and
Nod2-CARDs, were successfully synthesized using the wheat
germ cell-free system (Figure 1(d)). FLAG-RICK-WT and
FLAG-RICK-CARDwere also successfully synthesized using
the wheat germ cell-free system (Figure 1(e)).
3.2. MDP-Induced Interaction between Nod2 and RICK
in Nodosome in a Cell-Free System. Nod2-WT-Btn was
coprecipitated with FLAG-RICK-WT when incubated with
5.33mg/mL MDP, but not without MDP in pull-down assay
(Figure 2(a)). The baseline ALPHA signal of Nod2-WT-
Btn and FLAG-RICK-WT interaction was approximately
2000 counts, with no stimulation (Figure 2(b)). The ALPHA
signal of interaction between Nod2-WT-Btn and FLAG-
RICK-WT increased upon incubation with 5.33mg/mL
MDP (Sigma-Aldrich, St. Louis, MO, USA) (𝑝 < 0.01),
whereas no increase was detected upon incubation with the
same amount (5.33mg/mL) of N-Acetylmuramyl-D-Alanyl-
D-Isoglutamine (MDP-D-isomer) (Invivogen, San Diego,
CA, USA) (Figure 2(b)). The ALPHA signal of interaction
between Nod2-CARDs-Btn and FLAG-RICK-WT increased
without MDP (𝑝 < 0.01). Furthermore, the ALPHA signal
of interaction between Nod2-CARDs-Btn and FLAG-RICK-
CARD without MDP was significantly increased (𝑝 < 0.01),
whereas the ALPHA signal of interaction between Nod2-
WT-Btn and FLAG-RICK-CARD was not increased and was
similar to baseline levels (Figure 2(b)).
3.3. The MDP Degradation Products Did Not Induce Inter-
action between Nod2 and RICK in the Cell-Free System.
Using the Nod2-nodosome in a cell-free system established
above, we assessed whetherMDP degradation products, such
as L-alanine, D-isoglutamic acid, and N-acetylglucosamine
(GlcNAc), could induce interaction between Nod2 and RICK
in the cell-free system. No increased signals were observed
upon incubation with a negative control (−), MDP-D-isomer,
L-alanine, D-isoglutamic acid, and GlcNAc (Figure 2(c)).
3.4. ALPHA Signal in Response to MDP Was Observed in
Nod2-Nodosome in aCell-Free SystemContaining the BS/EOS-
AssociatedMutations. To test the activity of Nod2-nodosome
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Figure 1: Schematic representation of Nod2 and RICK, and sequencing chromatograms of Nod2 plasmids containing the BS/EOS-associated
mutations, and protein syntheses. (a) Schematic representations of biotinylated wild-type and mutant Nod2. C-terminal biotinylated full-
length wild-type Nod2 (Nod2-WT-Btn), full-length R334W-mutated Nod2 (Nod2-R334W-Btn), full-length N670K-mutated Nod2 (Nod2-
N670K-Btn), and tandem CARD1- and CARD2-domains-only Nod2 (Nod2-CARDs) are indicated. (b) Schematic representations of FLAG-
tagged wild-type and CARD-domain-only RICK. N-terminal FLAG-tagged full-length RICK (FLAG-RICK-FL) and CARD-domain-only
RICK (FLAG-RICK-CARD) are indicated. The caspase recruitment domain (CARD) is indicated by black boxes. The nucleotide-binding
oligomerization domain-containing protein (Nod) is indicated by grey boxes. Leucine-rich repeats are indicated by striped boxes. Amino acid
sequence number and mutated amino acids are indicated under each schema. (c) Sequencing chromatograms of Nod2 and mutated-Nod2
plasmids.The wild-type andmutated-Nod2 plasmids pDONR221-Nod2-WT, pDONR221-Nod2-R334W, and pDONR221-Nod2-N670Kwere
sequenced to confirm (from CGG to TGG corresponding to R334W in the right panel; from AAC to AAA corresponding to N670K in the
left panel) mutations at the appropriate site. (d) Western blotting analysis of biotinylated Nod2 and its mutants. A total of 1.5𝜇g of synthetic
proteinwas subjected to SDS-PAGE followed byWestern blotting. Protein detection on themembranes was performed usingHRP-conjugated
streptavidin. Molecular weights are indicated at right. (e) Western blotting analysis of FLAG-tagged RICK and CARD-domain-only RICK.
A total of 1.5𝜇g of synthetic protein was subjected to SDS-PAGE followed by Western blotting. Protein detection on the membranes was
performed using anti-FLAG mAb M2. Molecular weights are indicated at right.
































































































































Figure 2: Construction of Nod2-nodosome containing the BS/EOS-associated mutation in a cell-free system. Synthetic protein-protein
interactions were detected by pull-down assay and amplified luminescent proximity homogeneous assay (ALPHA). (a) Biotinylated-Nod2-
WT (Nod2-WT-Btn) and 1 𝜇g FLAG-tagged RICK-WT (FLAG-RICK-WT) lysed in 300𝜇L NP-40 buffer were precipitated with 20 𝜇L
streptavidin-conjugated agarose beads with or withoutMDP.The precipitations were subjected to SDS-PAGE and immunoblotting. Detection
on the blotting membranes was performed using anti-FLAG mAb M2 or anti-Nod2 mAb. (b) A total of 100 ng of each protein indicated
was incubated with 5 𝜇g/mL anti-FLAGmAbM2, 16.67 𝜇g/mL protein-A-conjugated ALPHA acceptor beads, and 16.67 𝜇g/mL streptavidin-
conjugated ALPHA donor beads for 24 hours, with or without 5.33mg/mL MDP or 5mg/mL N-Acetylmuramyl-D-Alanyl-D-Isoglutamine
(MDP-D-isomer). Responses (counts) were measured using the EnSpire Multimode Plate Reader. (c) Activation of Nod2-nodosome in a
cell-free system by MDP degradation components. Interactions between Nod2-WT-Btn and FLAG-RICK-WT were detected by ALPHA. A
total of 100 ng of Nod2-WT-Btn and FLAG-RICK-WTwere incubated with 5 𝜇g/mL anti-FLAGmAbM2, 16.67 𝜇g/mL protein-A-conjugated
ALPHA acceptor beads and 16.67 𝜇g/mL streptavidin-conjugated ALPHA donor beads for 24 hours, without or with 5.33mg/mL MDP,
5.33mg/mL MDP (D-isomer), 5.33mg/mL N-acetylglucosamine (GlcNAc), 5.33mg/mL L-alanine (L-Ala), or 5.33mg/mL D-isoglutamine
(D-isoGlu). Responses (counts) weremeasured using the EnSpireMultimode Plate Reader.The results are representative of three independent
experiments and given as means ± standard deviation from triplicate wells. (d) A total of 100 ng of Nod2-WT-Btn, or Nod2-R334W-Btn,
or Nod2-N670K-Btn with FLAG-RICK-WT was incubated with 5𝜇g/mL anti-FLAG mAb M2, 16.67 𝜇g/mL protein-A-conjugated ALPHA
acceptor beads, and 16.67 𝜇g/mL streptavidin-conjugatedALPHAdonor beads for 24 hours, with orwithout 5.33mg/mLor 13.33mg/mLMDP
or 13.33mg/mL MDP-D-isomer. The results are representative of three independent experiments and given as means ± standard deviation
from triplicate wells. CARD, caspase recruitment domain; MDP, muramyl dipeptide; WT, wild-type; P, precipitation; WB, western blot. ∗𝑝
value < 0.05 and ∗∗𝑝 value < 0.01 were considered statistically significant using Student’s 𝑡-test.
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in a cell-free system with or without BS/EOS-associated
mutations, we assessed the interaction between FLAG-RICK-
WTandNod2-WT-Btn,Nod2-R334W-Btn, orNod2-N670K-
Btn, in a cell-free system.The ALPHA signal between FLAG-
RICK-WT and Nod2-WT-Btn increased upon incubation
with 5.33mg/mL and 13.33mg/mLMDP, in a dose-dependent
manner (Figure 2(d)). The baseline ALPHA signal between
the BS/EOS-associatedNod2mutants, such asNod2-R334W-
Btn and Nod2-N670K-Btn, and FLAG-RICK-WT with no
stimulation was higher than that between Nod2-WT-Btn
and FLAG-RICK-WT (𝑝 < 0.01, 𝑝 < 0.01, resp.) (Fig-
ure 2(d), left columns). Upon incubation with 5.33mg/mL,
the ALPHA signal between Nod2-WT-Btn and FLAG-RICK-
WT increased in a dose-dependent manner, and signals
between Nod2-R334W-Btn or Nod2-N670K-Btn and FLAG-
RICK-WT were more significantly increased (𝑝 < 0.05,
𝑝 < 0.01, resp.) (Figure 2(d), center columns). Upon incu-
bation with 13.33mg/mL MDP, the ALPHA signal between
Nod2-WT-Btn and FLAG-RICK-WT increased in a dose-
dependent manner, and signals between Nod2-R334W-Btn
or Nod2-N670K-Btn and FLAG-RICK-WT were more sig-
nificantly increased (𝑝 < 0.05, 𝑝 < 0.01, resp.) (Figure 2(d),
right columns).
4. Discussion
Autoinflammatory syndromes are known to stem from aber-
rant innate immune complex disorders, some of which are
known to be due to the excessive innate immune activation
by mutations of the pathogen-recognizing receptors [17].
BS/EOS is one of the autoinflammatory syndromes, which is
characterized by systemic chronic granulomatous inflamma-
tion, resulting in nonnecrotizing granuloma of the skin, eyes,
and joints [12].The susceptibility gene product of BS/EOS has
been identified to be Nod2/CARD15 [11, 18].
In the present study, we developed Nod2-nodosomes
containing wild-type and the BS/EOS-associated mutants
R334W andN670K in a cell-free system, assessed by ALPHA.
In general, recombinant protein synthesis has been used
for bacterial or viral systems, such as Escherichia coli, for
structural and functional studies.However, synthetic proteins
sometimes are unable to be investigated, because many
proteins are expressed in an insoluble form [19].Therefore, we
employed the wheat germ cell-free protein synthesis system,
and Nod2-WT-Btn, Nod2-R334W-Btn, Nod2-N670K-Btn,
Nod2-CARDs, FLAG-RICK-WT, and FLAG-RICK-CARD
were successfully synthesized (Figure 1). To date, we reported
the generation of AIM2-inflammasome in a cell-free system,
which is another intracellular pattern recognition receptor
with adaptor ASC oligomerization, which was suitable for
wheat germ cell-free protein synthesis [20]. These results
suggested that the wheat germ cell-free protein synthesis sys-
tem has an advantage for reconstituting intracellular pattern
recognition receptor complexes for resolving innate immune
complex-mediated autoinflammatory diseases.
First, we confirmed whether the Nod2-nodosome could
recognize the bacterial cell-wall component MDP, which
is a previously reported Nod2-ligand [6, 7]. As shown in
Figure 2(a), Nod2-WT-Btn was coprecipitated with FLAG-
RICK-WT when incubated with MDP, but not without
MDP in pull-down assay (Figure 2(a)). That was consistent
with ALPHA in Figure 2(b). As shown in Figure 2(b), the
ALPHA signal of interaction between Nod2-WT-Btn and
FLAG-RICK-WT was increased upon incubation with MDP,
but not without a ligand or with the MDP-D-isomer or
MDP-degraded components (Figures 2(b) and 2(c)). These
results indicated that Nod2-nodosome in a cell-free system
is capable of detecting for its specific ligand, MDP.
Next, we tested whether the BS/EOS-associated Nod2
mutations induced increased activity. As shown in Fig-
ure 2(d), the ALPHA signal of interaction between FLAG-
RICK-WT and Nod2-R334W-Btn or Nod2-N670K-Btn was
much higher than when with Nod2-WT-Btn, with or without
MDP stimulation (Figure 2(d)). These results are consis-
tent with previous studies on the clinical manifestations of
BS/EOS [21], suggesting that Nod2-nodosome in a cell-free
system may suitably reflect the characteristics of endogenous
Nod2-nodosome.
It is noted that there are some limitations of nodosome
in a cell-free system. Only the initial event of Nod2-RICK
interaction is detected. Upstream, downstream, and regula-
tory events in the activation of Nod2 cannot be measured
with the nodosome in a cell-free system, as presented.
In conclusion, we developed Nod2-nodosome in a cell-
free system, assessed by ALPHA. Nod2-nodosomes con-
taining the BS/EOS-associated mutations Nod2-R334W and
Nod2-N670K were more sensitive to MDP than Nod2-
WT. Therefore, the Nod2-nodosomes in a cell-free system
developed in the present study can be a useful tool for further
investigation of pathogenesis of BS/EOS and discovery of its
therapeutics.
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